Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.

JACC: CardioOncology, published by Elsevier, is a pioneering open-access journal that has been at the forefront of the intersection between cardiology and oncology since its inception in 2019. With a focus on innovative research aimed at understanding the cardiovascular implications of cancer therapies, it has swiftly achieved recognition, holding a prestigious Q1 category ranking in both Cardiology and Cardiovascular Medicine and Oncology as of 2023. The journal's high impact factor and notable Scopus rankings—20th out of 387 in Cardiology and 44th out of 404 in Oncology—underscore its essential role in disseminating cutting-edge findings that inform clinical practices and improve patient outcomes. JACC: CardioOncology aims to provide a comprehensive platform for researchers, healthcare professionals, and students to share and access vital information, facilitating collaborations that advance knowledge in this critical field. With its commitment to open access, the journal ensures that groundbreaking research is readily available to a global audience, fostering an inclusive environment for academia and practice alike.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Journal of Veterinary Cardiology is a leading scientific publication dedicated to the field of veterinary cardiology, published by ELSEVIER. With an ISSN of 1760-2734 and E-ISSN 1875-0834, this journal plays a crucial role in disseminating cutting-edge research and clinical insights into animal cardiovascular health. With a strong emphasis on the interrelations of veterinary science and physiology, it boasts an impressive ranking in the Q1 category for miscellaneous veterinary studies and a significant position at 69th percentile in general veterinary rankings according to Scopus. Researchers, professionals, and students are encouraged to engage with the journal's diverse array of articles that span basic research to clinical applications, bridging knowledge gaps in veterinary cardiology. This important resource showcases impactful studies from its inception in 1999 and remains a steadfast conduit for the advancement of knowledge in the field through 2024 and beyond.

Cardiology Research is a prominent open-access journal dedicated to advancing the field of cardiology and cardiovascular medicine, published by ELMER PRESS INC. Renowned for its rigorous peer-review process, the journal provides a platform for cutting-edge research and innovative clinical practices in cardiology. With an ISSN of 1923-2829 and an E-ISSN of 1923-2837, it has established an impactful presence in the academic community, achieving a 2023 Scopus quartile ranking of Q3 in its category, positioning it in the 41st percentile. The journal's scope encompasses various aspects of cardiology research, including but not limited to epidemiology, diagnostics, therapeutics, and cardiovascular interventions. Although it operates without open access in certain contexts, it provides flexible access options for readers, ensuring that its valuable insights are widely disseminated. Cardiology Research is an essential resource for researchers, healthcare professionals, and students who aspire to stay at the forefront of cardiovascular science, contributing significantly to the global discourse on heart health.

Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

TEXAS HEART INSTITUTE JOURNAL, published by the renowned Texas Heart Institute, stands as a pivotal resource in the field of cardiology and cardiovascular medicine. With a history spanning over four decades since its establishment in 1982, this journal addresses a wide range of topics within its scope, including clinical studies, innovative treatments, and groundbreaking research in heart health. Despite its Q3 ranking in both Cardiology and Cardiovascular Medicine, the journal is committed to fostering advancement in medical knowledge and practice, providing an essential platform for healthcare professionals and researchers alike. While currently lacking open access, the journal is recognized for its contributions to the field, aiming to illuminate critical healthcare discussions and promote the exchange of ideas. For those interested in staying at the forefront of cardiovascular research, TEXAS HEART INSTITUTE JOURNAL offers invaluable insights and the latest developments shaping the future of heart care.

HEART FAILURE REVIEWS is a premier academic journal published by Springer, dedicated to the dynamic field of cardiology and cardiovascular medicine. With an impressive Q1 ranking in 2023, the journal stands as a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments in heart failure management and research. Covering a broad spectrum of topics, including innovative therapies, epidemiology, and pathophysiology of heart failure, it fosters an environment for interdisciplinary collaboration. The journal is indexed with an ISSN of 1382-4147 and an E-ISSN of 1573-7322, ensuring widespread dissemination of knowledge. Although it does not currently offer open access options, its rigorous peer-review process guarantees high-quality content that contributes significantly to the scientific community. Established in 1996 and running through 2024, HEART FAILURE REVIEWS continues to be a leading platform for advancing understanding and treatment of heart conditions, making it an indispensable resource for all stakeholders in cardiac health.